[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant

111.O1.6 111. Hemoglobinopathies, excluding Thalassemia: Sickle Cell Disease - Therapeutic Interventions

Program: Oral and Poster Abstracts
Type: Oral
Sunday, December 11, 2011: 4:30 PM-6:00 PM
Elizabeth Ballroom AB (Manchester Grand Hyatt San Diego)
Kathryn L. Hassell, MD, University of Colorado Denver Health Sciences Center and Thomas D. Coates, MD, Children's Hospital Los Angeles

Hassell: Emmaus, Inc: Research Funding; NIH: Investigator, Steering Committee Co-Chari, WalkPHaSST Study; Apotex: Consultancy; Glycomimetics, Inc: Research Funding. Coates: Novartis Pharma: Speakers Bureau; ApoPharma: Consultancy.
4:30 PM
Hydroxyurea Treatment of Young Children with Sickle Cell Anemia:  Safety and Efficacy of Continued Treatment -- the BABY HUG Follow-up StudyClinically Relevant Abstract

Zora R. Rogers, MD1, Billie Fish, CCRP2*, Zhaoyu Luo, PhD2*, Rathi V. Iyer, MD3, Courtney D. Thornburg, MD, MS4, Sharada A. Sarnaik, MD5, Sohail R. Rana, MD6*, Lori Luchtman-Jones, MD7, Sherron M. Jackson, MD8*, Thomas H. Howard, MD9, James F. Casella, MD10, R. Clark Brown, MD, PhD11, Ofelia A. Alvarez, MD12, Jonathan C. Goldsmith, MD13, Scott T. Miller, MD14 and Winfred C. Wang, MD15

1Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX
2Clinical Trials & Surveys Corporation , Owings Mills, MD
3University if Mississippi, Jackson, MS
4Duke University Medical Center, Durham, NC
5Children's Hosp. of Michigan, Detroit, MI
6Howard University, Washington, DC
7Children's National Medical Center, Washington, DC
8Medical University of South Carolina, Charleston, SC
9University of Alabama at Birmingham, Birmingham, AL
10The Johns Hopkins University School of Medicine, Baltimore, MD
11Emory University / Children's Healthcare of Atlanta, Atlanta, GA
12Univ. of Miami School of Med., Miami, FL
13National Heart Lung and Blood Institute, NIH, Bethesda, MD
14SUNY - Brooklyn, Brooklyn, NY
15 , St. Jude Children's Research Hospital, Memphis, TN

4:45 PM
Genotoxicity Associated with Hydroxyurea Exposure in Infants with Sickle Cell Anemia: Results From the BABY-HUG Phase III Clinical TrialClinically Relevant Abstract

Patrick T. McGann, MD1, Jonathan M Flanagan, PhD2, Thad A Howard, MS2*, Stephen D Dertinger, PhD3*, Jin He, MD4*, Anita S Kulharya, PhD5*, Bruce W Thompson, PhD6* and Russell E. Ware, MD, PhD2

1Texas Children's Hospital Hematology Center, Baylor College of Medicine, Houston, TX
2Baylor College of Medicine, Houston, TX
3Litron Laboratories, Rochester, NY
4St. Jude Children's Research Hospital, Memphis, TN
5Pathology, Georgia Health Sciences University, Augusta, GA
6Clinical Trials and Surveys Corp., Owings Mills, MD

5:00 PM
Pre-Operative Transfusion Reduces Serious Adverse Events in Patients with Sickle Cell Disease (SCD): Results From the Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) Randomised Controlled Multicentre Clinical TrialClinically Relevant Abstract

Jo Howard, MB, BChir, MRCP, FRCPath1*, Moira Malfroy, RN2*, Llewelyn Charlotte, PhD2*, Louise Choo, PhD3*, David Rees, FRCPath4*, Isabeau Walker, FRCA5*, Tony Johnson, PhD3*, Louise Tillyer, FRCPath6*, Karin Fijnvandraat, MD, PhD7, Melanie Kirby-Allen, MD8*, Renate Hodge, MSc2*, Shilpi Purohit2*, Sally C. Davies, FRCP, FMedSci9 and Lorna M Williamson, FRCPath2*

1Haematology, Guy's and St Thomas' NHS Foundation Trust, LONDON, United Kingdom
2NHSBT/MRC Clinical Studies Unit, NHS Blood and Transplant
3Clinical Trials Unit, Medical Research Council
4Haematology, Kings College Hospital NHS Foundtion Trust
5Great Ormond Street Hospital NHS Trust
6Haematology, Royal Brompton and Harefield NHS Foundation Trust
7Academic Medical Center (AMC), Amsterdam, Netherlands
8Hospital for Sick Children Toronto
9Department of Health, London

5:15 PM
Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for Patients with Severe Sickle Cell Disease (SCD)Clinically Relevant Abstract

Matthew M Hsieh1*, Courtney D Fitzhugh, MD1, R. Patrick Weitzel, PhD2*, Wynona Coles1*, M Beth Link3* and John F. Tisdale1

1MCHB, NHLBI, NIH, Bethesda, MD
2Mchb, NHLBI, NIH, Bethesda, MD
3NHLBI/MCHB, NIH, Bethesda, MD

5:30 PM
Bone Marrow Transplantation Arrests Cerebrovascular Disease Progression and Improves Psychometric Outcomes in Children with Sickle Cell Disease

Neha Bhatnagar, MBChB, MRCPCH1*, Ruth Erskine2*, Farah O'Boyle3*, Subarna Chakravorty, PhD, FRCPath, MRCPCH4*, Irene Roberts, MD5 and Josu de la Fuente, PhD, FRCP, FRCPath4

1The Department of Haematology, Imperial College London, London, United Kingdom
2Division of Paediatrics, St. Mary's Hospital, London, United Kingdom
3Department of Haematology, Imperial College London, London, United Kingdom
4Imperial College London, London, United Kingdom
5Department of Haematology, Imperial College at Hammersmith Hospital, London, United Kingdom

5:45 PM
Age-Related Blood Transfusion Patterns in Patients with Sickle Cell Disease (SCD) and the Association with Sickle Cell ComplicationsClinically Relevant Abstract

Morey A. Blinder, MD1, Francis Vekeman, MA2*, Alex Trahey, BA2*, Medha Sasane, PhD3*, Carole S. Paley, MD4 and Mei Sheng Duh, MPH, ScD2

1Medicine, Pathology and Immunology, Washington University School of Medicine, St. Louis
2Analysis Group, Inc., Boston, MA
3Novartis Pharmaceutical Corporation, East Hanover, NJ
4Novartis Pharmaceuticals Corporation, East Hanover, NJ

*signifies non-member of ASH